| Bioactivity | Berubicin (RTA 744 free base; WP 744) is a 4'-O-benzyldoxorubicin that inhibits P-gp and MRP1-mediated efflux and has anticancer activity. Berubicin inhibits glioblastoma multiforme (GBM) and exhibits cytotoxicity. Berubicin has poor bioavailability in mice[1]. | |||||||||
| CAS | 677017-23-1 | |||||||||
| Formula | C34H35NO11 | |||||||||
| Molar Mass | 633.64 | |||||||||
| Appearance | 固体 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Kazerooni R, et al. Phase I clinical pharmacokinetics of RTA 744 (berubicin (B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol)[J]. Molecular Cancer Therapeutics, 2007, 6(11_Supplement): B101-B101. |
Berubicin
CAS: 677017-23-1 F: C34H35NO11 W: 633.64
Berubicin (RTA 744 free base; WP 744) is a 4'-O-benzyldoxorubicin that inhibits P-gp and MRP1-mediated efflux and has an
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.